Injecting Proviron or Masteron into gyno lump

Forums ANABOLIC STEROIDS – QUESTIONS & ANSWERS Injecting Proviron or Masteron into gyno lump

  • Post
    Lawnmover
    Member
    Blows my mind. You guys ever hear of this protocol to get RID of existing gyno? I mean if it’s legit, I would be happy to be rid of these tits I’ve had since puberty.

    quoting from another forum:

    "Per 1ml so that it could be pinned 3 hours preworkout everyday and still maintain stable blood levels of the two. However this is slightly off topic.

    If the mole people on this forum take anything from my posts in this thread, take away this:

    If you want to get PREVENT Gyno and estrogenic side effects, run every cycle with 50-100mg Proviron , 200-500mg Masteron , or any other dry form of DHT, primobolan etc. (NOT anadrol ).

    If you want to get RID of Gyno, take a 31G slin pin and inject 150mg of Masteron or Proviron into the lump. OR inject 500mg Masteron a day until it goes away. Pramipexole is also very useful in the treatment and prevention of Gyno as Prolactin has a significant effect on estrogen’s proliferation at breast tissue.

    DHT is the best thing to use to combat estrogenic side effects of ANY steroid . SERM’s suck. fact.
    I would be very impressed if you got Gyno from 2000mg Testosterone run with 500mg Masteron. Unless your Prolactin was high.

    You are taking a risk running Tren with anything estrogenic without DHT. Also **** your hair, just shave it off I don’t want to hear anyone bitching. "

Viewing 2 replies - 16 through 17 (of 17 total)
  • Replies
    Lawnmover
    Member
    Quote Originally Posted by renepjdView
    The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. – PubMed – NCBI

    Thought I posted this in this thread. Must have been a different one…

    Excellent read.

    "The in vivo Km values were estimated to be 1.83 nm for aromatase and 3.35 nm for 5alpha-reductase, independent of age."

    They talked about ratios, but only E2:T and DHT:T, not DHT:E2 ratios. DHT:E2 would be 3.35/1.83= 1.83

    If you used an AI to cut aromatization in half, then the ratio of DHT:E2 would be 3.35/.91= 3.68. This leads to gyno prevention/reduction.
    If you injected DHT or derivatives, to increase DHT by 50%, then the ratio of DHT:E2 = 5.025/1.83 = 2.74 This has been proposed to lead to gyno prevention/removal.

    So you see my point. The avenues are different, but the destinations, thereby, the direction of change in hormonal results, are the same.

    Thoughts:
    -I could be missing some details. Ears are wide open.
    -Locally injecting DHT into the breast lump- can DHT work locally? or does it play by the same rules of others, needing to pass the liver first and travel the blood?
    -Assuming aromatization to be at exactly 50%, or injecting DHT to exactly double, is obviously for exploring the topic only. No way to be that precise.
    -Their math seems unusually round, it’s normally not the case right? To say that aromatization occurs at exactly half the conversion to DHT? That is what their numbers say.

    In all I’m just demonstrating my point of curiosity. I haven’t proved anything right, but this sort of analysis does support what the gentlemen from the other board proposed.

    So who wants to try it out first?

    Lawnmover
    Member
    Worth pointing others to, and generally excellent read and it has citations!

    Before I post. Is there any way to obtain DHT? Most injectable are DHT derivatives. Where do you find 100% DHT topicals or injectables? Still a newb.

    The link:
    16 Ways to Fight Gynecomastia

    The quotes:
    "1. Your naturally occurring 5a-reduced metabolites are your friends in preventing and reversing gyno. 5a-reduced metabolites include androsterone, androstanedione, androstanediol and dihydrotestosterone (DHT) as the most powerful 5a-reduced hormone. These hormones help prevent gyno by lowering estrogen and blocking the effect of estrogen at the hormone receptor. (1-8) Unless you have serious androgen related hair loss you want to keep your 5a-reduced metabolites relatively high to avoid gyno.

    Methods for increasing 5a-reduced metabolites (DHT) are listed in preferred order –

    Topical testosterone applied to the sBambtum will rapidly increase DHT levels with minimal estrogen conversion. (for more information on topical steroids , read this article)
    Use a DHT pro-hormone such as androsterone, found in AndroHard. This will raise DHT with zero risk of estrogen conversion.
    Injectable testosterone along with an AI to prevent excessive estrogen conversion.
    High dose oral 4-DHEA or DHEA along with an AI to prevent excessive estrogen conversion.
    2. If you are concerned about gyno, avoid finesteride at all costs. It lowers all 5a-reduced metabolites to undesirable levels and has an extremely long half-life which continues to suppress DHT levels long after discontinuing the drug. (9) Progesterone would be a better anti-DHT alternative if you are concerned with hair loss. Plus, progesterone can clear the system within 24hrs making a mistake in dosing much less risky.

    3. Almost all sources of gyno can be linked back to having insufficient levels of 5a-reduced metabolites in the body. In theory, any amount of estrogen/progesterone can be blocked by sufficient DHT. (10-14) Also, high DHT and enlargement of the prostate is a myth, however high estrogen and high DHT can lead to an inflamed prostate, so you want to at least make an effort to keep estrogen in a normal range. (14)

    4. Trenbolone , TREN , Nandrolone can cause gyno because they lack a potent 5a-reduced metabolite (dihydronandrolone is weaker than dihydrotestosterone). (15) If you are worried about gyno from progestational steroids you should consider boosting your 5a-reduced metabolites during the cycle (mentioned above). This can avoid most if not all of the gyno problems associated with progestational hormones. I should mention here that aromatase inhibitors alone (AI’s) will not help prevent gyno from progestational compounds. It is the antagonistic action of 5a-reduced hormones that is required.

    5. Nothing is going to antagonize estrogen at the estrogen receptor (ER) better than actual DHT. While DHT derivatives or analogs such as Anavar , Winstrol , Masteron , Epistane, Superdrone, ect may be 5a-reduced, they cannot convert to actual DHT and thus cannot directly inhibit gyno at the receptor level (since they lack the ultra-high binding affinity for the AR that true DHT possesses). (16)

    6. Natural anti-estrogens (resveratrol, chrysin, I3C, DIM, ect) are great for PCT and can stimulate the HPTA and manage healthy estrogen metabolism, but they are not strong enough to prevent aromatization from high doses of aromatizing steroids. Don’t rely on these to prevent gyno during a cycle.

    7. Reducing prolactin will reduce the overall stimulation on mammary growth. Suppressing prolactin is useful as a temporary method to help slow or stop gyno growth. However, continuing anti-prolactin treatment is not recommended to be continued beyond 8 weeks. Methods of suppressing prolactin include –

    Vitex at 460mg/day
    Vitamin B6 at 200-400mg/day
    Mucuna Pruriens (15%-20% L-Dopa) 4-6g/day
    Increasing DHT may also lower prolactin release (17)
    8. Don’t fiddle with your nipples. This increases prolactin release which can make gyno worse.

    9. IGF-1, GH, insulin and prolactin are all potent growth factors in gyno growth. Limiting these hormones will reduce the likelihood of experiencing gyno symptoms. “Bulking” (aka., eating-a-****load-of-everything) will increase most of the growth factors listed above. Cutting calories (especially DikkIyhydrates) will suppress insulin and IGF-1 therefore reducing the overall stimulatory effect on mammary growth. Ketogenic diet = less risk of gyno.

    10. Body fat (adipose tissue) is the main site for androgens to convert to estrogens. Therefore, being overweight or having high body fat increases your gyno risk. This is another good reason to go on a cutting cycle if you are gyno prone. Reducing body fat will lower your rate of estrogen conversion from aromatizing steroids. (18)

    11. Caffeine consumption can inhibit clearance of estrogen from the liver by competing for the P-450 oxidase system. Avoid caffeine if you are concerned about high estrogen levels.

    12. Avoid supplements containing forskolin if concerned about gyno. Forskolin increases aromatase activity via cAMP modulation and can increase formation of estrogen. (23,24)

    13. Increasing fiber intake (both soluble and insoluble) can enhance clearance of estrogens from the intestines. Research shows that increasing fiber intake in humans can reduce estrogen levels by up to 22%. (19)

    14. Reducing estrogen below the normal range (such as over dosing arimidex , letrozol, aromasin or formestane) can eventually reduce SHRonin levels, thus allowing more estrogen to freely circulate (by offsetting it from SHRonin). Higher levels of freely circulating estrogen can amplify breast tissue growth (20). SHRonin also appears to have anti-estrogenic effects at the cell receptor level. (21, 22) Avoiding over suppression of SHRonin will reduce your gyno risk.

    15. Don’t be afraid to lower the dose mid cycle. People have a tendency to panic at the first sign of gyno and drop everything. Generally, just lowering the dose of the afflicting steroid can offer gyno relief within 4-5 days.

    16. Save SERM’s as your last resort against gyno. You do not need a SERM (tormifene, clomid or nolva) to avoid gyno from a properly planned cycle. If you are still having gyno problems after following the above points, consider the fact that you have a poorly planned cycle and you need to revaluate the compounds you have chosen.

    References –

    1. Dihydrotestosterone may inhibit hypothalamo-pituitary-aCrash007al activity by acting through estrogen receptor in the male mouse.
    Lund TD, et al.
    Neurosci Lett. 2004 Jul 15;365(1):43-7.

    2. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor.
    Szelei J, et al.
    Tufts University School of Medicine, Department of Anatomy and Cellular Biology, Boston, Massachusetts 02111, USA.

    3. The non-aromatizable androgen, dihydrotestosterone, induces antiestrogenic responses in the rainbow trout.
    Shilling TII, et al.
    Agricultural and Life Sciences Building, room 1007, Oregon State University, Corvallis, OR 97331, USA.

    4. The androgen 5alpha-dihydrotestosterone and its metabolite 5alpha-androstan-3beta, 17beta-diol inhibit the hypothalamo-pituitary-aCrash007al response to stress by acting through estrogen receptor beta-expressing neurons in the hypothalamus.
    Lund TD, et al.
    J Neurosci. 2006 Feb 1;26(5):1448-56.

    5. Steroid modulation of aromatase activity in human cultured breast carcinoma cells.
    Perel E, et al.
    J Steroid Biochem. 1988 Apr;29(4):393-9.

    6. Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation.
    Killinger DW, et al.
    Steroids. 1987 Oct-Dec;50(4-6):523-36. Review.

    7. The intracellular control of aromatase activity by 5 alpha-reduced androgens in human breast carcinoma cells in culture.
    Perel E, et al
    J Clin Endocrinol Metab. 1984 Mar;58(3):467-72.

    8. FSH-induced aromatase activity in porcine granulosa cells: non-competitive inhibition by non-aromatizable androgens.
    Chan WK, et al
    J Endocrinol. 1986 Mar;108(3):335-41.

    9. The effect of 5 alpha-reductase inhibitors on erectile function.
    Canguven O, Burnett AL.
    J Androl. 2008 Sep-Oct;29(5):514-23.

    10. Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men – A Clinical Research Center Study*
    C. Wang et al.
    Journal of Clinical Endocrinology and Metabolism Vol. 83, No. 8 (1998)

    11. Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: four cases and a review of the literature.
    Benveniste O et al.
    Clin Infect Dis. 2001 Sep 15;33(6):891-3.

    12. Gynecomastia: effect of prolonged treatment with dihydrotestosterone by the percutaneous route.
    Kuhn J et al.
    Presse Med 12;21-25. (1983)

    13. Percutaneous dihydrotestosterone (DHT) treatment. In: Nieschlag E, Behre HM, eds. Testosterone: action, deficiency substitution.
    Schaison G, Nahoul K, Couzinet B.
    Berlin: Springer Verlag; 155–164. (1990)

    14. Transdermal dihydrotestosterone and treatment of ‘andropause ’.
    de Lignieres B.
    Ann Med 1993;25: 235–41.

    15. Metabolism and receptor binding of nandrolone and testosterone under invitro and invivo conditions.
    Bergink et al.
    Acta Endocrinol Suppl (Copenh). 271:31-7, 1985

    16. Pharmacology of Reproduction
    David E, et al.
    Principles of Pharmacology (second edition) p. 510 (2008)

    17. Antagonism of estrogen-induced prolactin release by dihydrotestosterone.
    Brann DW, et al.
    Biol Reprod. 1989 Jun;40(6):1201-7.

    18. Aromatase – a brief overview
    Simpson ER, et al
    Annu Rev Physiol. 64:93-127, 2002

    19. Dietary fiber intake and endogenous serum hormone levels in naturally postmenopausal Mexican American women: the Multiethnic Cohort Study.
    Monroe KR et al.
    Nutr Cancer. 2007;58(2):127-35.

    20. Williams Textbook of Endocrinology.
    Wilson, et al.
    9th ED. Philadelphia: Saunders, 1997

    21. Sex steroid binding protein receptor (SBP-R) is related to a reduced proliferation rate in human breast cancer.
    Catalano MG, et al.
    Breast Cancer Res Treat. 42(3):227-34, 1997

    22. Biological relevance of the interaction between sex steroid binding protein and its specific receptor of MCF-7 cells under SBP and estradiol treatment.
    Fissore F, et al.
    Steroids, 59(11):661-7, 1994

    23. Progestin-dependent effect of forskolin on human endometrial aromatase activity.
    Tseng L, Malbon CC, Lane B, Kaplan C, Mazella J, Dahler H, Tseng A.
    Hum Reprod. 1987 Jul;2(5):371-7.

    24. Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human aCrash007ocortical carcinoma cell line H295R.
    Watanabe M, Nakajin S.
    J Endocrinol. 2004 Jan;180(1):125-33."

Viewing 2 replies - 16 through 17 (of 17 total)
  • You must be logged in to reply to this topic.